New drug combo targets tough blood cancers
NCT ID NCT02935361
First seen Jan 29, 2026 · Last updated May 11, 2026 · Updated 13 times
Summary
This study tests a combination of two drugs, guadecitabine and atezolizumab, in adults with myelodysplastic syndrome or chronic myelomonocytic leukemia that has spread, returned, or not responded to prior treatment. The goal is to find the best dose and see how well the drugs work together to control the disease. About 33 participants will be enrolled in this early-phase trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111, United States
-
Temple University Hospital
Philadelphia, Pennsylvania, 19140, United States
-
USC / Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
-
University of Maryland Medical Center
Baltimore, Maryland, 21201, United States
Conditions
Explore the condition pages connected to this study.